Category Archives: Delinkage

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Pay big pharma to solve antibiotics crisis, says UK government review

The Guardian; Pharmaceutical companies should be given cash incentives of up to $3bn to find and develop new antibiotics desperately needed to keep infections at bay, according to a UK government review. Jim O’Neill, the economist and former chair of … Continue reading

Posted in Antibiotics, Delinkage, Innovation | Leave a comment

Talking drug prices #6: Openness vs. secrecy in drug development

Plos Blogs. October 22, 2015. By Mat Todd Contributors in this series on drug prices and access to medicines have mentioned important issues related to policy, finance and intellectual property. I’d like to make a few comments from the point of view … Continue reading

Posted in Delinkage, Innovation, Open access, Pricing | Leave a comment

Talking about drug prices #5. Double-billed: Why we’re paying high prices for drugs – and why we shouldn’t need to

Plos Blogs; October 21, 2015.By Manica Balasegaram, MSF Access to Medicines Last month, Martin Shkreli, the CEO of Turing Pharmaceuticals, acquired Daraprim, a 60 year-old drug used to treat toxoplasmosis, and unapologetically raised the price 5,500% overnight. Shkreli caused such outrage … Continue reading

Posted in Delinkage, Innovation, Pricing | Leave a comment

Talking Drug Prices #4: Drug pricing is out of control, what should be done?

Plos Blogs, October 19, 2015. By James Love, International intellectual property rights analyst, Knowledge Ecology International Today we are confronted with three related set of issues dealing with the pricing of new drugs, vaccines and medical devices. There are cases where older … Continue reading

Posted in Delinkage, Innovation, Pricing, Trade Agreements | Leave a comment

Chatham House Report On Antibiotics Gives Evidence For Drug R&D Delinkage

Source: IP watch, October 9, 2015 A new report from Chatham House presenting suggestions for novel business models for antibiotics calls for models in which the return on investment in research and development is not dependent on the volume of … Continue reading

Posted in Antibiotics, Delinkage, Innovation, Tuberculosis (TB) | Leave a comment